Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;20(9):581-582.
doi: 10.1038/s41571-023-00795-6.

A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma

Kathryn E Beckermann  1 , Brian I Rini  2
Affiliations

A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma

Kathryn E Beckermann et al. Nat Rev Clin Oncol. 2023 Sep.
No abstract available

PubMed Disclaimer

References

    1. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018). - DOI - PubMed - PMC
    1. Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019). - DOI - PubMed
    1. Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021). - DOI - PubMed
    1. Williams, S. D., Loehrer, P. J., Nichols, C. R. & Einhorn, L. N. Chemotherapy of male and female germ cell tumors. Semin. Oncol. 19(Suppl 5), 19–23 (1992). discussion 23–24. - PubMed
    1. Choueiri, T. K. et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N. Engl. J. Med. 388, 1767–1778 (2023). - DOI - PubMed

MeSH terms

LinkOut - more resources